{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:02:36Z","timestamp":1788210156519,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11255-017-1615-x","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T15:57:26Z","timestamp":1494863846000},"page":"1691-1697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-1633","authenticated-orcid":false,"given":"Theodoros","family":"Eleftheriadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Pissas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sounidaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Antoniadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Antoniadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Liakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Stefanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"issue":"23","key":"1615_CR1","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341(23):1725\u20131730. doi: 10.1056\/NEJM199912023412303","journal-title":"N Engl J Med"},{"issue":"3","key":"1615_CR2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","volume":"4","author":"HU Meier-Kriesche","year":"2004","unstructured":"Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4(3):378\u2013383","journal-title":"Am J Transplant"},{"issue":"25","key":"1615_CR3","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, Study EL-S (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357(25):2562\u20132575. doi: 10.1056\/NEJMoa067411","journal-title":"N Engl J Med"},{"issue":"6","key":"1615_CR4","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/ndt\/gfp778","volume":"25","author":"H Ekberg","year":"2010","unstructured":"Ekberg H, Bernasconi C, Noldeke J, Yussim A, Mjornstedt L, Erken U, Ketteler M, Navratil P (2010) Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 25(6):2004\u20132010. doi: 10.1093\/ndt\/gfp778","journal-title":"Nephrol Dial Transplant"},{"issue":"1 Suppl","key":"1615_CR5","first-page":"s12","volume":"21","author":"C Enderby","year":"2015","unstructured":"Enderby C, Keller CA (2015) An overview of immunosuppression in solid organ transplantation. Am J Manag Care 21(1 Suppl):s12\u2013s23","journal-title":"Am J Manag Care"},{"issue":"6","key":"1615_CR6","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1053\/j.ajkd.2015.01.026","volume":"65","author":"DE Hricik","year":"2015","unstructured":"Hricik DE (2015) Transplant immunology and immunosuppression: core curriculum 2015. Am J Kidney Dis 65(6):956\u2013966. doi: 10.1053\/j.ajkd.2015.01.026","journal-title":"Am J Kidney Dis"},{"issue":"4\u20135","key":"1615_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clinbiochem.2016.02.001","volume":"49","author":"LE Becker","year":"2016","unstructured":"Becker LE, Morath C, Suesal C (2016) Immune mechanisms of acute and chronic rejection. Clin Biochem 49(4\u20135):320\u2013323. doi: 10.1016\/j.clinbiochem.2016.02.001","journal-title":"Clin Biochem"},{"key":"1615_CR8","unstructured":"Rapamune (sirolimus) [package insert] (2012) Wyeth Pharmaceuticals Inc, Philadelphia, PA"},{"key":"1615_CR9","unstructured":"Zortress (everolimus) [package insert] (2013) Novartis Pharmaceuticals Corp, East Hanover, NJ"},{"key":"1615_CR10","unstructured":"Prograf (tacrolimus) [package insert] (2013) Astellas Pharma US, Northbrook, IL"},{"issue":"1","key":"1615_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","volume":"90","author":"L Chan","year":"2010","unstructured":"Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM (2010) Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 90(1):31\u201337. doi: 10.1097\/TP.0b013e3181de1d67","journal-title":"Transplantation"},{"issue":"12","key":"1615_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/intimm\/dxu077","volume":"26","author":"T Eleftheriadis","year":"2014","unstructured":"Eleftheriadis T, Pissas G, Antoniadi G, Spanoulis A, Liakopoulos V, Stefanidis I (2014) Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. Int Immunol 26(12):673\u2013684. doi: 10.1093\/intimm\/dxu077","journal-title":"Int Immunol"},{"issue":"2","key":"1615_CR13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2249.1999.00784.x","volume":"115","author":"T Sato","year":"1999","unstructured":"Sato T, Deiwick A, Raddatz G, Koyama K, Schlitt HJ (1999) Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol 115(2):301\u2013308","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"1615_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/imm.12502","volume":"146","author":"T Eleftheriadis","year":"2015","unstructured":"Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I (2015) Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells. Immunology 146(2):292\u2013300. doi: 10.1111\/imm.12502","journal-title":"Immunology"},{"issue":"1","key":"1615_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1128\/CVI.00347-07","volume":"15","author":"E Konishi","year":"2008","unstructured":"Konishi E, Kitai Y, Kondo T (2008) Utilization of complement-dependent cytotoxicity to measure low levels of antibodies: application to nonstructural protein 1 in a model of Japanese encephalitis virus. Clin Vaccine Immunol 15(1):88\u201394. doi: 10.1128\/CVI.00347-07","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"1615_CR16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-1759(91)90114-U","volume":"142","author":"NW Roehm","year":"1991","unstructured":"Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL (1991) An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 142(2):257\u2013265","journal-title":"J Immunol Methods"},{"issue":"5","key":"1615_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/tan.12454","volume":"84","author":"M Lindemann","year":"2014","unstructured":"Lindemann M (2014) Ex vivo assessment of cellular immune function\u2014applications in patient care and clinical studies. Tissue Antigens 84(5):439\u2013449. doi: 10.1111\/tan.12454","journal-title":"Tissue Antigens"},{"issue":"2","key":"1615_CR18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.128.2.696","volume":"128","author":"HC Rumke","year":"1982","unstructured":"Rumke HC, Terpstra FG, Huis B, Out TA, Zeijlemaker WP (1982) Immunoglobulin production in human mixed lymphocyte cultures: implications for co-cultures of cells from patients and healthy donors. J Immunol 128(2):696\u2013701","journal-title":"J Immunol"},{"issue":"1","key":"1615_CR19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jps.2600820121","volume":"6","author":"Z Wang","year":"2003","unstructured":"Wang Z, Chen HT, Roa W, Finlay W (2003) Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharm Sci 6(1):95\u2013100","journal-title":"J Pharm Pharm Sci"},{"key":"1615_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.12659\/AOT.890673","volume":"19","author":"L Rostaing","year":"2014","unstructured":"Rostaing L, Christiaans MH, Kovarik JM, Pascual J (2014) The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. Ann Transplant 19:337\u2013345. doi: 10.12659\/AOT.890673","journal-title":"Ann Transplant"},{"issue":"1","key":"1615_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","volume":"83","author":"K Budde","year":"2015","unstructured":"Budde K, Rath T, Sommerer C, Haller H, Reinke P, Witzke O, Suwelack B, Baeumer D, May C, Porstner M, Arns W (2015) Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clin Nephrol 83(1):11\u201321","journal-title":"Clin Nephrol"},{"issue":"4","key":"1615_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","volume":"92","author":"H Holdaas","year":"2011","unstructured":"Holdaas H, Rostaing L, Seron D, Cole E, Chapman J, Fellstrom B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O\u2019Connell PJ, Investigators A (2011) Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 92(4):410\u2013418. doi: 10.1097\/TP.0b013e318224c12d","journal-title":"Transplantation"},{"issue":"10","key":"1615_CR23","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","volume":"12","author":"L Mjornstedt","year":"2012","unstructured":"Mjornstedt L, Sorensen SS, von Zur Muhlen B, Jespersen B, Hansen JM, Bistrup C, Andersson H, Gustafsson B, Undset LH, Fagertun H, Solbu D, Holdaas H (2012) Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 12(10):2744\u20132753. doi: 10.1111\/j.1600-6143.2012.04162.x","journal-title":"Am J Transplant"},{"issue":"9768","key":"1615_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","volume":"377","author":"K Budde","year":"2011","unstructured":"Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, Investigators ZS (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768):837\u2013847. doi: 10.1016\/S0140-6736(10)62318-5","journal-title":"Lancet"},{"issue":"3","key":"1615_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/tri.12252","volume":"27","author":"SJ Chadban","year":"2014","unstructured":"Chadban SJ, Eris JM, Kanellis J, Pilmore H, Lee PC, Lim SK, Woodcock C, Kurstjens N, Russ G, Group SS (2014) A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int 27(3):302\u2013311. doi: 10.1111\/tri.12252","journal-title":"Transpl Int"},{"issue":"2","key":"1615_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","volume":"159","author":"S Heidt","year":"2010","unstructured":"Heidt S, Roelen DL, Eijsink C, Eikmans M, van Kooten C, Claas FH, Mulder A (2010) Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 159(2):199\u2013207. doi: 10.1111\/j.1365-2249.2009.04051.x","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"1615_CR27","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3892\/ijmm.2016.2547","volume":"37","author":"T Eleftheriadis","year":"2016","unstructured":"Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Tsogka K, Sounidaki M, Stefanidis I (2016) Differential effects of the two amino acid sensing systems, the GCN2 kinase and the mTOR complex 1, on primary human alloreactive CD4(+) T-cells. Int J Mol Med 37(5):1412\u20131420. doi: 10.3892\/ijmm.2016.2547","journal-title":"Int J Mol Med"},{"issue":"9","key":"1615_CR28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1097\/TP.0b013e3181874a36","volume":"86","author":"S Heidt","year":"2008","unstructured":"Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A (2008) Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 86(9):1292\u20131300. doi: 10.1097\/TP.0b013e3181874a36","journal-title":"Transplantation"},{"issue":"1","key":"1615_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40620-014-0134-4","volume":"28","author":"K Budde","year":"2015","unstructured":"Budde K, Sommerer C, Rath T, Reinke P, Haller H, Witzke O, Suwelack B, Baeumer D, Sieder C, Porstner M, Arns W (2015) Renal function to 5\u00a0years after late conversion of kidney transplant patients to everolimus: a randomized trial. J Nephrol 28(1):115\u2013123. doi: 10.1007\/s40620-014-0134-4","journal-title":"J Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-017-1615-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:30:31Z","timestamp":1692804631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-017-1615-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1007\/s11255-017-1615-x","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]}}}